Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReLUTH: Retreatment With Lutathera in Progressive Intestinal Neuroendocrine Tumors
NCT04954820Phase 2Recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Oct 2021
- Primary completion
- Oct 2033
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by Institut du Cancer de Montpellier. Started Oct 2021; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04954820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954820.